GlassScriptPhysician profile
Mateen Akhtar
NPI 1053389668
$856.61
in general payments reported to CMS, 2019-2025
12 companies · $60.62 in 2025
The $60.62 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.89 · 2020: $10.06 · 2021: $117 · 2022: $212 · 2023: $159 · 2024: $232 · 2025: $60.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $432.31 | 2020-2023 | Lifevest |
| Irhythm Technologies, INC. | $183.41 | 2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $48.63 | 2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $47.23 | 2021-2025 | Triclip |
| Alnylam Pharmaceuticals INC. | $27.52 | 2022 | |
| Lundbeck LLC | $20.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.89 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.36 | 2019 | |
| Shockwave Medical, INC | $16.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.73 | 2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $14.08 | 2019 | |
| Pfizer INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mateen Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.